Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR) announced U.S. FDA Fast Track designation for KT-621, a first-in-class oral STAT6 degrader for moderate to severe eosinophilic asthma.
KT-621 is in global Phase 2b trials for asthma and atopic dermatitis, with asthma data expected in late 2027 and AD data by mid-2027.
Kymera (NASDAQ: KYMR) announced Gilead Sciences exercised its option to exclusively license KT-200, an oral CDK2 molecular glue degrader, triggering a $45 million milestone payment. Gilead will advance KT-200 into IND-enabling studies aiming for an IND filing in 2027. Kymera remains eligible for up to $750 million in total payments and tiered royalties.
Preclinical data cited low-nanomolar CDK2 degradation, activity in CCNE1-amplified models, brain-penetrant potential, and a favorable safety profile.
Kymera Therapeutics (NASDAQ: KYMR) reported positive Phase 1b BroADen results for oral STAT6 degrader KT-621, presented at AAD 2026. In 22 moderate-to-severe atopic dermatitis patients, 28-day dosing produced median STAT6 degradation up to 98% in blood and meaningful reductions in clinical and biomarker endpoints.
Parallel Phase 2b trials in atopic dermatitis (BROADEN2) and asthma (BREADTH) are ongoing, with data expected by mid-2027 and late-2027, respectively.
Kymera Therapeutics (NASDAQ: KYMR) announced that data from its KT-621 BroADen Phase 1b trial in moderate-to-severe atopic dermatitis will be presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
The oral session is scheduled for March 28, 2026 at 9:24 AM MT in Bellco Theatre, Denver. Kymera will also host a booth (#3551) in the exhibit hall. A copy of the presentation will be posted in Kymera's Resource Library after the session.
Kymera Therapeutics (NASDAQ: KYMR) reported Q4 and full-year 2025 results, advanced multiple clinical programs, and strengthened its balance sheet. Key highlights include $1.6 billion in cash (runway into 2029), positive KT-621 Phase 1b atopic dermatitis data, FDA Fast Track for KT-621, initiation of KT-579 Phase 1 dosing, and ongoing KT-621 Phase 2b studies with data expected mid-2027 (AD) and late-2027 (asthma).
Kymera Therapeutics (NASDAQ: KYMR) will take part in multiple investor conferences and fireside chats in early March 2026, including TD Cowen (March 3), UBS Biotech Summit (March 9), Leerink (March 10), Jefferies Biotech on the Beach (March 11), and Barclays (March 12).
Live webcasts of each presentation will be available under News and Events in the Investors section of the company website, with replays archived after the events.
Kymera Therapeutics (NASDAQ: KYMR) will report fourth quarter and full year 2025 financial results on February 26, 2026 and will host a video conference call and webcast at 8:30 a.m. ET.
Investors can register to join the live video call or view the livestreamed webcast via the company website; a replay will be archived after the event.
Kymera Therapeutics (NASDAQ: KYMR) announced participation in two investor fireside chats in February 2026. The company will present at Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 at 9:00 a.m. ET and at Oppenheimer Virtual Healthcare Life Sciences on Feb 26, 2026 at 2:00 p.m. ET.
Live webcasts and archived replays will be available in the Investors section of the company website under “News and Events.”
Kymera Therapeutics (NASDAQ: KYMR) announced dosing of the first patient in the BREADTH Phase 2b trial of KT-621, an oral STAT6 degrader for moderate to severe eosinophilic asthma. The randomized, double-blind, placebo-controlled study will enroll ~264 adults across three dose arms over 12 weeks.
The company expects BREADTH data in late-2027 and parallel BROADEN2 atopic dermatitis data by mid-2027, aiming to inform dose selection for subsequent Phase 3 registrational studies.
Kymera Therapeutics (NASDAQ: KYMR) outlined 2026 objectives to advance its oral immunology portfolio, highlighting clinical and preclinical milestones for STAT6 degrader KT-621 and IRF5 degrader KT-579.
Key points: KT-621 BROADEN2 Phase 2b in atopic dermatitis (enrollment complete in 2026; data mid-2027), BREADTH Phase 2b in eosinophilic asthma initiated (data late-2027), and FDA Fast Track in AD (Dec 2025). KT-579 Phase 1 healthy volunteer trial to start in 1Q26 with data in 2H26. Company reports $1.6 billion cash runway into 2029 and plans to advance at least one new development candidate toward IND in 2026.